Iovance Biotherapeutics (IOVA) Income towards Parent Company: 2010-2025
Historic Income towards Parent Company for Iovance Biotherapeutics (IOVA) over the last 9 years, with Sep 2025 value amounting to -$91.3 million.
- Iovance Biotherapeutics' Income towards Parent Company fell 9.23% to -$91.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$397.7 million, marking a year-over-year increase of 2.99%. This contributed to the annual value of -$372.2 million for FY2024, which is 16.18% up from last year.
- Iovance Biotherapeutics' Income towards Parent Company amounted to -$91.3 million in Q3 2025, which was up 18.28% from -$111.7 million recorded in Q2 2025.
- In the past 5 years, Iovance Biotherapeutics' Income towards Parent Company ranged from a high of -$78.6 million in Q4 2024 and a low of -$116.4 million during Q4 2023.
- In the last 3 years, Iovance Biotherapeutics' Income towards Parent Company had a median value of -$107.4 million in 2023 and averaged -$103.2 million.
- As far as peak fluctuations go, Iovance Biotherapeutics' Income towards Parent Company skyrocketed by 32.47% in 2024, and later fell by 15.05% in 2025.
- Quarterly analysis of 3 years shows Iovance Biotherapeutics' Income towards Parent Company stood at -$116.4 million in 2023, then spiked by 32.47% to -$78.6 million in 2024, then fell by 9.23% to -$91.3 million in 2025.
- Its Income towards Parent Company stands at -$91.3 million for Q3 2025, versus -$111.7 million for Q2 2025 and -$116.2 million for Q1 2025.